binding buffer Search Results


alphalisa buffer  (Revvity)
91
Revvity alphalisa buffer
(A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
Alphalisa Buffer, supplied by Revvity, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/alphalisa buffer/product/Revvity
Average 91 stars, based on 1 article reviews
alphalisa buffer - by Bioz Stars, 2026-04
91/100 stars
  Buy from Supplier
annexin v binding buffer  (Miltenyi Biotec)
97
Miltenyi Biotec annexin v binding buffer
(A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
Annexin V Binding Buffer, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/annexin v binding buffer/product/Miltenyi Biotec
Average 97 stars, based on 1 article reviews
annexin v binding buffer - by Bioz Stars, 2026-04
97/100 stars
  Buy from Supplier
annexin v binding buffer  (SouthernBiotech)
93
SouthernBiotech annexin v binding buffer
(A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
Annexin V Binding Buffer, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/annexin v binding buffer/product/SouthernBiotech
Average 93 stars, based on 1 article reviews
annexin v binding buffer - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
dna  (MACHEREY NAGEL)
93
MACHEREY NAGEL dna
(A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
Dna, supplied by MACHEREY NAGEL, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dna/product/MACHEREY NAGEL
Average 93 stars, based on 1 article reviews
dna - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
pcr clean up kit  (MACHEREY NAGEL)
94
MACHEREY NAGEL pcr clean up kit
(A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
Pcr Clean Up Kit, supplied by MACHEREY NAGEL, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcr clean up kit/product/MACHEREY NAGEL
Average 94 stars, based on 1 article reviews
pcr clean up kit - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
binding buffer  (Elabscience Biotechnology)
95
Elabscience Biotechnology binding buffer
(A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
Binding Buffer, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/binding buffer/product/Elabscience Biotechnology
Average 95 stars, based on 1 article reviews
binding buffer - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
mapsii binding buffer  (Bio-Rad)
85
Bio-Rad mapsii binding buffer
(A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
Mapsii Binding Buffer, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mapsii binding buffer/product/Bio-Rad
Average 85 stars, based on 1 article reviews
mapsii binding buffer - by Bioz Stars, 2026-04
85/100 stars
  Buy from Supplier
annexin v binding buffer  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology annexin v binding buffer
(A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
Annexin V Binding Buffer, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/annexin v binding buffer/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
annexin v binding buffer - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
annexin v binding buffer  (Cytek Biosciences)
94
Cytek Biosciences annexin v binding buffer
(A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
Annexin V Binding Buffer, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/annexin v binding buffer/product/Cytek Biosciences
Average 94 stars, based on 1 article reviews
annexin v binding buffer - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
binding buffer  (MACHEREY NAGEL)
90
MACHEREY NAGEL binding buffer
(A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
Binding Buffer, supplied by MACHEREY NAGEL, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/binding buffer/product/MACHEREY NAGEL
Average 90 stars, based on 1 article reviews
binding buffer - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
macherey nagel pcr clean up kit  (MACHEREY NAGEL)
94
MACHEREY NAGEL macherey nagel pcr clean up kit
(A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
Macherey Nagel Pcr Clean Up Kit, supplied by MACHEREY NAGEL, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/macherey nagel pcr clean up kit/product/MACHEREY NAGEL
Average 94 stars, based on 1 article reviews
macherey nagel pcr clean up kit - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
sb binding buffer  (MACHEREY NAGEL)
92
MACHEREY NAGEL sb binding buffer
(A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) <t>AlphaLISA</t> screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .
Sb Binding Buffer, supplied by MACHEREY NAGEL, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sb binding buffer/product/MACHEREY NAGEL
Average 92 stars, based on 1 article reviews
sb binding buffer - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier

Image Search Results


(A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) AlphaLISA screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .

Journal: Cell reports

Article Title: HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide

doi: 10.1016/j.celrep.2023.112755

Figure Lengend Snippet: (A) VRC 018 clinical regimen and a flowchart for B cell sorting and antibody screening. (B) Single B cell sorting with glycan-base BG505 trimer probes reveals only a small fraction of memory B cells from VRC 018 clinical trial to be directed to the glycan-dense surface of the Env trimer versus its glycan-free base. (C) AlphaLISA screening of RATP-Ig supernatants from sorted B cells for antibodies that bind both BG505 DS-SOSIP and glycan-base BG505. Data were measured in triplicates; error bars represent standard error of the mean (SEM). (D) Apparent affinity measurement of top antibodies from AlphaLISA screening for binding to BG505 DS-SOSIP and glycan-base BG505 trimers. Antibody IgGs were expressed and purified, and their binding to trimers was measured by Carterra. 2G12 and VRC01 were used as positive controls. Motavizumab was used as negative control, and no binding was observed. (E) Antibodies 2C06 and 2C09 neutralize BG505, but no other tested strains. Asterisk denotes tier status for BI369.9A unknown but resistant to antibodies 17b, 48d, F105, 3074, and 447-52D that neutralize only laboratory-adapted strains. Neutralization for other antibodies from (D) that bind glycan-base BG505 are shown in . (F) Affinity of antibody Fabs binding to BG505 DS-SOSIP trimer, measured by SPR. Data in (D) and (F) were measured once and the curves fitted with a simple 1:1 Langmuir binding model for the reported mean ± SEM. See also and .

Article Snippet: RATP-Ig supernatants from glycan-base BG505-positive B cells were diluted into AlphaLISA buffer (PBS +0.05% Tween 20 + 0.5 mg/mL BSA), and 5 μL of each were transferred to an OptiPlate-384 assay plate (white opaque, PerkinElmer, Waltham, MA).

Techniques: FACS, Glycoproteomics, Binding Assay, Purification, Negative Control, Neutralization